MedTrace Logo

Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer

NCT00967824 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1683

Last updated 2011-03-24

No results posted yet for this study

Summary

RATIONALE: Evaluating a decision aid that describes the risks and benefits of taking tamoxifen citrate to prevent breast cancer may be helpful for women at increased risk of breast cancer.

PURPOSE: This randomized phase I/II trial is studying tamoxifen citrate decision aids for women at increased risk of breast cancer.

Conditions

Interventions

OTHER

informational intervention

OTHER

questionnaire administration

OTHER

survey administration

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Angela Fagerlin, PhD · University of Michigan Rogel Cancer Center

Study Design

Allocation
RANDOMIZED

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967824 on ClinicalTrials.gov